| abstract |
The invention refers to liposomal formulations containing an antibiotic, comprising drug/lipid ratios up to 10 mg/100 mg lipid, the size of liposomes ranging from 5 νm to 0.01 νm and the encapsulation efficiencies typically being greater than 60 %. The liposomal antibiotics, when administered to animals, increase the half-life circulation time in plasma, efficiently reduce the acute toxicity and increase the antimicrobial activities, compared to the free drugs. The invention also refers to a process for the preparation of liposomal formulations comprising forming multilamellar liposomes containing the antibiotic and subjecting the liposomes to lyophilization, rehydration and optionally extrusion under pressure. |